Opportunty Alert: EMERGEAZ Fast Grants

In partnership with the Arizona Governor’s Office, invisionAZ and StartupAZ are offering financial support to the state’s startups through the EMERGEAZ Fast Grant. Local entrepreneurs and startups with emerging technologies designed to address the impacts of the pandemic are encouraged to apply. There is a total of $1 million in the fund and grants will be awarded in amounts ranging from $25,000 to $50,000.Continue reading

Record Number of Startups Currently Enrolled in the University of Arizona Center for Innovation

Rapid growth seen from entrepreneurs who want to make a significant difference in the local and global communities through innovation. 

TUCSON, Ariz. (January 15, 2021) — The University of Arizona Center for Innovation (UACI) is pleased to announce that more than 40 startups, a record number, are enrolled in the incubation program. Passionate entrepreneurs from across the nation have flocked to UACI. Each one of the 40+ tech and science-based startups are developing solutions for real-world problems and have a strong desire to make a significant difference in the local and global communities through innovation.  

Continue reading

C-Path Announces SHIP-MD 2021 Virtual Workshop

Multi-stakeholder event will focus on national innovation ecosystem for pediatric medical device development

TUCSON, Ariz., January 14, 2021 — The Critical Path Institute (C-Path) in collaboration with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health (CDRH), AdvaMed, the American Academy of Pediatrics (AAP) and multiple pediatric health system leaders, is proud to announce the System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) Virtual Workshop to be held on February 9-11, 2021. The workshop will focus on the acceleration of medical device development for the unique needs of children.

Continue reading

FDA Releases Final Rule on the Safer Technologies Program for Medical Devices (STeP)

The FDA is introducing a new, voluntary program for certain medical devices and device-led combination products1 that are reasonably expected to significantly improve the safety of currently available treatments or diagnostics that target an underlying disease or condition associated with morbidities and mortalities less serious than those eligible for the Breakthrough Devices Program.

Learn about the  Safer Technologies Program for Medical Devices (STeP) program 

Continue reading

Johnson & Johnson COVID-19 Vaccine Candidate Interim Phase 1/2a Data Published in New England Journal of Medicine

January 13, 2021 — Interim Phase 1/2a data were published today in the New England Journal of Medicine demonstrating that the Company’s single-dose investigational COVID-19 vaccine candidate (JNJ-78436735) – being developed by the Janssen Pharmaceutical Companies of Johnson & Johnson – provided an immune response that lasted for at least 71 days, the duration of time measured in this study in participants aged 18-55 years. A preview of part of these interim data was posted on medRxiv in September 2020.

Continue reading